

QUANTITATIVE IMAGING WORKSHOP XIX:

Utilizing Quantitative Thoracic Imaging
to Optimize Population Health

November 3-4, 2022 | Virtual

Speaker Biographies



SAMUEL M. AGUAYO, MD

Dr. Samuel Aguayo is associate chief of staff for research at Phoenix Veterans Affairs (VA) Health Care System. His lifelong professional efforts and personal interests are largely dedicated to the better understanding and the treatment of tobacco-related lung diseases such as lung cancer and chronic obstructive pulmonary disease (COPD), which are devastating among Veterans. As an extension of his interest in lung cancer, Dr. Aguayo serves as the Phoenix VA site principal investigator (PI) for the collaborative project, “Risk Prediction of Lung Cancer in People 40 Years of Age and Older.” Results from this project will hopefully benefit the Veteran population, especially those who served during the Gulf War and in Iraq and/or Afghanistan where risk factors other than smoking may also play a role in their increased susceptibility to develop lung cancer.

This project will enhance the knowledge of risk factors for lung cancer and may significantly contribute to designing effective strategies for targeted and more effective screening of those at the highest risk. Dr. Aguayo’s extensive experience in successfully managed projects, collaborating with other researchers and producing several peer-reviewed abstracts and publications demonstrate his qualifications as a VA investigator. Results from these projects demonstrate Dr. Aguayo’s ability and expertise in conducting research, managing and supervising study teams, and engaging in active collaborations.

samuel.aguayo@va.gov

LinkedIn: www.linkedin.com/in/samuel-m-aguayo-md-8074352b



CAROLYN R. (“BO”) ALDIGÉ

Founder and Steering Committee Member, Quantitative Imaging Workshop

Carolyn Aldigé founded the Prevent Cancer Foundation® in 1985 in memory of her father who died of cancer one year earlier. The Prevent Cancer Foundation® is one of the nation’s leading voluntary health organizations and the only US nonprofit organization focused solely on cancer prevention and early detection.

Since 2004, Ms. Aldigé and the Prevent Cancer Foundation®—in cooperation with Foundation vice-chair and scientific director Dr. James Mulshine—have organized and hosted the Quantitative Imaging Workshop. Ms. Aldigé has served on boards of directors/advisors of eight National Cancer Institute-designated Cancer Centers, including the top-ranked MD Anderson Cancer Center and Vanderbilt Ingram Cancer Center. She is a member of the boards of directors of Friends of Cancer Research and the Intercultural Cancer Council, the Patient Advocate Advisory Board of Stand Up to Cancer, and the External Advisory Board of the Thoracic Oncology Center at Mount Sinai Medical Center.

Her international work includes serving as vice-chairman of the Global Lung Cancer Coalition, a member of the advisory board of the International Early Lung Cancer Action Program, the Advisory Board of Project ECHO and a member of the board of directors of the International Society for Cancer Prevention.

A 1996 Washingtonian of the Year, Ms. Aldigé is the only individual to have won public service awards from the American Association for Cancer Research, the American Society of Clinical Oncology and the American Society of Preventive Oncology. She has also been recognized with awards by several cancer-related nonprofit organizations, many of which have a focus on health equity.

carolyn.aldige@preventcancer.org

Twitter: [@preventcancer](https://twitter.com/preventcancer)

LinkedIn: www.linkedin.com/in/carolyn-aldige-3574475



SAMUEL Y. ASH, MD, MPH

Dr. Samuel Ash is a pulmonologist and intensivist at Brigham and Women's Hospital in Boston, MA. He received his undergraduate degree from Yale University, his medical degree from the Columbia University and his master's degree in public health from the Harvard School of Public Health. He completed his residency and chief residency at the University of Washington in Seattle and his fellowship at the Brigham where is now a physician investigator in the Applied Chest Imaging Laboratory and an assistant professor of Medicine at Harvard Medical school. His research focuses on the development and integration of machine learning and computer vision based tools for the diagnosis and understanding of conditions ranging from emphysema to acute respiratory distress syndrome.

syash@bwh.harvard.edu

Twitter: [@yoffeash](https://twitter.com/yoffeash)

LinkedIn: www.linkedin.com/in/samuel-ash-b67a09a/



RICARDO AVILA, MS

Steering Committee Member, Quantitative Imaging Workshop

Ricardo Avila is a computer scientist and CEO of Accumetra, Inc., a high-performance imaging services company focused on advancing the science of image-based decision making. Mr. Avila has extensive experience leading the development of health care applications in academic, government and commercial settings, including at Howard Hughes Medical Institute, GE Global Research, Kitware and the United States Department of Veterans Affairs. His main area of expertise is in the development of computer-aided detection algorithms for early lung cancer and the quantitative measurement of lung nodule size change over time. Throughout his career, he has contributed to several open science projects including major open source initiatives (VTK, ITK and OSEHRA) as well as Give-A-Scan, a patient donated and openly available CT scan database for accelerating lung cancer research. Mr. Avila received a master's degree in computer science from the State University of New York at Stony Brook, specializing in 3D biomedical imaging and visualization.

rick.avila@accumetra.com

LinkedIn: www.linkedin.com/in/ricardo-avila-1687451



MIRZA FAISAL BEG, PhD, PEng

Dr. Mirza Faisal Beg is a professor in the School of Engineering Science at Simon Fraser University (SFU). He is also the chief executive and the chief scientific officer of Voronoi Health Analytics Inc., a Vancouver Canada-based company building software platforms for body composition and organ/tissue measurements from medical images. He received his bachelor of technology (honors) degree in Electrical Engineering at the Indian Institute of Technology (IIT), Kharagpur; his master of science degree in Biomedical Engineering from Boston University (USA); and his PhD degree in Biomedical Engineering from Johns Hopkins University (USA). He was recognized with the SFU Faculty of Applied Science's Excellence in Teaching award (2011) the Association of Professional Engineers and Geoscientists of British Columbia's Meritorious Achievement award (Presidential Award, 2012) for his contributions to engineering and computational tools for advancing technology applicable to human health; and the SFU Faculty of Science Excellence in Research Award (2015). His expertise is in developing novel AI, machine learning, medical imaging analysis, computer vision and signal processing tools and applying them to extract biomedical imaging-based biomarkers for the quantitative understanding of human anatomy structure and function.

mfbeg@voronoihealthanalytics.com

Twitter: [@VoronoiHealth](https://twitter.com/VoronoiHealth)

LinkedIn: <https://www.linkedin.com/in/mirza-faisal-beg-89ba27/>



BRANDON CONROY

Brandon Conroy is a vice president of Underwriting and Actuarial at Magellan Health. He is a credentialed actuary and has over 25 years of experience in the actuarial field with various roles. Mr. Conroy has spent time as a health actuary at health plans, consulting firms and a data analytics company. He currently is responsible for pricing and analyzing carve out health programs for health plans across the country including RBM, radiation oncology, musculoskeletal, behavioral health, physical medicine, sleep testing and genetic testing.

conroyb@magellanhealth.com

LinkedIn: www.linkedin.com/in/brandon-conroy-4380bb1



DEBRA S. DYER, MD, FACR

Dr. Debra Dyer is a fellowship trained cardiothoracic radiologist and professor of Diagnostic Radiology and serves as chair of the Department of Radiology at National Jewish Health, a chronic respiratory disease hospital in Denver, CO. Throughout her career, Dr. Dyer has been committed to Quality Improvement in Diagnostic Radiology. She has implemented numerous Quality Improvement initiatives including programs in radiation dose reduction, the appropriate utilization of imaging and lung nodule management. She was instrumental in the creation of the National Jewish Health Lung Nodule Registry for incidental lung nodules, the first of its kind in the US. With a special interest in lung cancer screening CT, Dr. Dyer serves as the director of the Lung Cancer Screening program at National Jewish Health. She is the immediate past chair of the American College of Radiology Lung Cancer Screening 2.0 Steering Committee. Dr. Dyer is a past-chair of the Colorado Cancer Coalition and current co-chair of the Colorado Lung Cancer Task Force. Dr. Dyer has participated in numerous research studies and published several peer-reviewed articles on lung cancer screening and lung nodule management.

dyerd@njhealth.org



RAÚL SAN JOSÉ ESTÉPAR, PhD

Steering Committee Member, Quantitative Imaging Workshop

Dr. Raúl San José Estépar is co-director of the Applied Chest Imaging Laboratory at Brigham and Women's Hospital and associate professor of Radiology at Harvard Medical School. His laboratory focuses on novel computational imaging applications for image-based biomarker discovery to empower epidemiological and genetic studies and provide novel surrogate targets for drug discovery and clinical trial development. His group supports the image analytics of multiple Federal and Industry sponsored investigations serving as imaging core for COPDGene, the Framingham Heart Study Pulmonary Research Center, the CARDIA Lung Study and, more recently, the American Lung Association (ALA) Lung Health Cohort. Dr. San José Estépar is the original developer and chief architect of the Chest Imaging Platform, an open-source software platform for CT-based lung phenotyping. His research has made significant contributions to the quantitative study of pulmonary vascular remodeling and the subtyping and modeling of parenchymal lung injury. His current research interests are focused on artificial intelligence approaches to enable multiscale integration of imaging and molecular information using deep learning, synthetic lung functional imaging from single energy CT, and image-based outcomes prediction models in chronic lung diseases.

Dr. San José Estépar received his PhD in Telecommunications Engineering from the University of Valladolid, Spain, where he specialized in signal processing applied to medical image analysis and conducted his post-doc in the Surgical Planning Laboratory, Brigham and Women's Hospital. He has been faculty at Harvard Medical School since 2006. He has co-authored over 200 peer-reviewed manuscripts, and he is currently the principal investigator of several National Institutes of Health awards and industry sponsored studies. He is a member of the Fleischner Society, and he is actively involved in disseminating quantitative approaches for better healthcare delivery. He has been on the steering committee for the Quantitative Imaging Workshop since 2015. Dr. San José Estépar is also the founder and scientific advisor of Quantitative Imaging Solutions, a healthcare technology company that translates image-based AI solutions and modeling to detect and predict lung diseases.

rsanjose@bwh.harvard.edu



WENDY EVERETT, ScD

Dr. Wendy Everett is the vice president of advisory services at Avalere Health and serves as a senior advisor to other national health policy organizations. In 2002, she formed the Network for Excellence in Health Innovation (NEHI) and was its president and chief executive officer for 14 years. Along with NEHI's founders, Dr. Everett created NEHI as an independent, research-based organization that convened diverse members of the healthcare industry to address the most urgent healthcare issues. This collective vision resulted in ground-breaking research on medical innovation, patient safety, healthcare spending, and healthcare information technology, and has influenced significant national policy changes.

Previously, Dr. Everett held senior executive positions at the Brigham and Women's Hospital in Boston and at the University of California, San Francisco Medical Center. She has directed national demonstration programs for the Robert Wood Johnson Foundation and the Kaiser Family Foundation. She was the vice chair of the Massachusetts Health Policy Commission, an independent state agency that monitors the reform of the healthcare delivery and payment systems in Massachusetts and has become a model for the nation. She also serves on the boards of many philanthropic foundations, corporations, and non-profit organizations.

Dr. Everett earned two bachelor of science degrees and holds master's and doctoral degrees in health policy and management from Harvard University.

weverett@nehi-us.org

Website: nehi.net

LinkedIn: [linkedin.com/in/wendy-everett-scd-11257937](https://www.linkedin.com/in/wendy-everett-scd-11257937)



SEAN FAIN, PhD

Dr. Sean Fain is professor and vice chair of research in the Department of Radiology at University of Iowa. He previously served as professor of Medical Physics, Radiology and Biomedical Engineering at the University of Wisconsin – Madison. He now directs the Functional Lung Imaging Laboratory in the Iowa Institute for Biomedical Imaging. His research develops quantitative imaging methods using magnetic resonance imaging (MRI) and CT. His research is highly translational, including leadership roles in multi-center imaging studies of asthma (Severe Asthma Research Program; The Great Lakes PrecISE Partnership), and industry collaborations (GE Healthcare, Xemed LLC, Polarean, Imbio LLC) to improve quantitative measures of lung disease. He is the physics chair of the of the CT Lung Density Biomarker Committee of the Quantitative Image Biomarkers Alliance (QIBA) and is working with the COPD Foundation on quantitative CT imaging biomarkers of airway remodeling and parenchymal density to improve phenotyping of obstructive lung disease.

sean-fain@uiowa.edu

Twitter: [@bedilionfain](https://twitter.com/bedilionfain)

LinkedIn: www.linkedin.com/in/sean-fain-887ab178/



JOELLE FATHI, DNP, RN, ARNP, CTTs, FAAN

Dr. Joelle Fathi is the chief healthcare delivery officer at the GO2 Foundation for Lung Cancer. She is responsible for expanding excellence and high-quality care across the lung cancer continuum in communities nationwide and advocating for systems change, funding, and regulation to gain better access to care and optimal outcomes for marginalized and underserved populations. A board-certified and practicing nurse practitioner, Dr. Fathi has 30 years of experience in direct clinical care, including the thoracic oncology continuum. She is nationally certified as a tobacco treatment specialist and serves diligently to control tobacco and help people quit smoking. She is an associate teaching professor at the University of Washington School of Nursing. Dr. Fathi is a Fellow of the American Academy of Nursing for her distinguished contributions to improving health and achieving health equity by impacting policy through nursing leadership, innovation, and science. She serves in many leadership roles in healthcare, nursing, health policy, advisory boards, and national and international committees.

jfathi@go2foundation.org

Twitter: [@GO2Foundation](https://twitter.com/GO2Foundation)



TESSA F. FLORES, MD

Dr. Tessa Flores is the medical director of Cancer Screening and Survivorship at the Roswell Park Comprehensive Cancer Center. She also serves as an assistant professor of Oncology for the University of Buffalo's Jacobs School of Medicine & Biomedical Sciences. After obtaining her bachelor's degree in Biology and medical degree from West Virginia University, Dr. Flores completed her residency training at University of Buffalo Combined Internal Medicine and Pediatrics program and is a board-certified internist and pediatrician. Prior to working at Roswell Park Comprehensive Cancer Center, Dr. Flores practiced primary care in private practice, university teaching, and community health center settings. She is passionate about preventative care, wellness, cancer screening, and cancer survivorship.

tessafaye.flores@roswellpark.org

Twitter: [@RoswellPark](https://twitter.com/RoswellPark)



RICHARD FRANK, MD, PHD

Dr. Richard Frank is principal of Frank Healthcare Advisors, LLC, and a member of the American Medical Association's CPT® Editorial Panel which ensures that CPT® codes reflect the latest medical care available to patients. With over 30 years global experience in the design, regulatory labeling, public and private payment for, and clinical adoption of therapeutic and diagnostic drugs and devices, Dr. Frank offers a broad, real-world perspective on the evolving role of diagnostics in today's healthcare marketplace. Dr. Frank's similarly global experience with government agencies and non-governmental organizations (NGOs), and within both academia and industry, gives him particular expertise in clinical evidentiary standards, government policy, and the product-, market-, and delivery system-specific inefficiencies and issues that burden payers and delay or skew patients access to the benefits of innovation.

richardfrankcpt@gmail.com



SUSAN K. FRIED, PhD

Dr. Susan Fried is professor and director of Translational Adipose Biology and Obesity in the Diabetes, Obesity and Metabolism Institute at the Icahn School of Medicine at Mount Sinai. She earned a bachelor's degree in biology from Barnard College (1974), a master's in Human Nutrition from the Institute of Human Nutrition, Columbia College of Physicians and Surgeons and a PhD in Nutritional Biochemistry from Columbia University (1980). After post-doctoral work in Endocrinology at Emory University, and in Lipid Biochemistry at the Medical College of Pennsylvania, she returned to New York City to become a research associate at the New York Obesity Center. After that she became assistant professor in the Laboratory of Human Behavior and Metabolism at Rockefeller University and then moved up the faculty ranks to professor in the Department of Nutritional Sciences at Rutgers University. At the University of Maryland School of Medicine, Dr. Fried was the founding director of a National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-funded Clinical Nutrition Research Center / Nutrition Obesity Research Center (NORC) and then served at the director of the Boston NORC at the Boston University School of Medicine (BUSM). She was served director of the Graduate Program in Nutrition and Metabolism at BUSM. Her work has been well-funded by the National Institutes of Health and the American Diabetes Association, among others, for the past 40 years. Acknowledging her contributions of the field of nutrition and to its main professional society. Dr. Fried was elected as a Fellow of the American Nutrition Society in 2022.

susan.fried@mssm.edu



LEE GAZOURIAN, MD, MS

Dr. Lee Gazourian is the director of the Lung Health Program and co-director of research at the Lahey Hospital & Medical Center. His primary research interests are to apply quantitative Computer Tomography imaging technology to the lung cancer screening and general patient populations at Lahey. He is currently the principal investigator of a multi-center study utilizing the lung cancer screening cohorts at Lahey Hospital & Medical Center, Mount Auburn Hospital and Boston Medical Center. To date Lahey has screened over 10,000 patients and performed over 25,000 total CT scans. His research focuses on both objective and quantitative assessments of pulmonary and extra pulmonary manifestations of disease both at baseline and longitudinally. His group is currently evaluating the association between both quantitative and qualitative metrics, of emphysema, interstitial lung disease, coronary artery calcification, pulmonary vascular disease and body composition with clinical outcomes including cancer, hospitalizations and quality metrics including COPD/ILD screening, cardiovascular risk stratification, immunizations and smoking cessation.

With the support of Three Lakes Foundation, Dr. Gazourian has developed a novel Lung Health Clinical Program focused on early disease detection and leveraging incidental findings on Chest and abdominal imaging to improve patient care.

Dr. Gazourian received his medical doctorate from Boston University School of Medicine and his pulmonary and critical care training at the combined Harvard program.

lee.gazourian@lahey.org



LAURIE E. GIANTURCO, MD, CPE, DABR

Dr. Laurie Gianturco is the national medical director of Radiology for UnitedHealthcare. She is board certified in diagnostic and nuclear radiology and fellowship trained in interventional radiology and body imaging. In addition to more than 20 years of clinical practice experience, Dr. Gianturco was chair of Radiology at Baystate Medical Center and president of an independent radiology practice in the northeast. She served on the Massachusetts Radiology Society Executive Committee and the New England Society for Nuclear Medicine, chaired the Nuclear Medicine Subcommittee for Educational Exhibits for the Radiologic Society of North America (RSNA), and served as a board examiner for the American Board of Radiology.

Prior to joining UnitedHealthcare, Dr. Gianturco was chief medical officer for Health New England, a regional provider-owned health plan. She serves on the board of the Southeastern Vermont Community Action, which works to eliminate poverty, and as a volunteer for the Western Mass Medical Reserves Corp.

laurie.gianturco@uhc.com

LinkedIn: www.linkedin.com/in/laurie-gianturco-md



SYDNEY KANTOR

Sydney Kantor is a project manager with the **Early Lung and Cardiac Action Program (ELCAP)** at Mount Sinai Hospital in New York, NY. Currently an MBA candidate at Fordham University with a dual concentration in Healthcare Management and Marketing, Ms. Kantor has worked on the **Initiative for Early Lung Cancer Research on Treatment (IELCART)** project since 2017. This research collects data directly from patients and explores the various treatment options for early-stage lung cancer as well as the quality of life and survival of each patient over time. Additionally, Ms. Kantor works with the Mount Sinai marketing team to develop initiatives and events that the ELCAP program holds to raise awareness for lung screenings.

sydney.kantor@mountsinai.org



ELLA KAZEROONI, MD, MS

James L. Mulshine, MD, National Leadership Award Presenter

Dr. Ella Kazerooni's work in lung cancer screening research, coverage and implementation is extensive. She serves as the vice chair of the National Comprehensive Cancer Network (NCCN) Lung Cancer Screening panel, served as the inaugural chair of the American College of Radiology (ACR) Lung-RADS® committee and chairs the ACR's Lung Cancer Screening Registry (LCSR), and worked towards the ACR Designated Lung Cancer Screening program under the CT accreditation program. These efforts are focused on bringing quality lung cancer screening to high-risk individuals and reduce the mortality from the #1 cancer—killer. Most recently, Dr. Kazerooni was named the inaugural chair of the American Cancer Society's National Lung Cancer Roundtable. With a master's degree in Clinical Research Design & Statistical Analysis, Dr. Kazerooni's research focuses on the development and evaluation of advanced imaging technologies applied to the heart and lungs, including lung cancer screening, coronary artery and aortic disease, pulmonary embolism, and diffuse lung diseases. Her work in clinical and translational research earned her the University of Michigan Medical School's prestigious Clinical and Health Services Researcher of the Year award.

ellakaz@med.umich.edu

Twitter: [@ellakaz](https://twitter.com/ellakaz)

**ANITA MCGLOTHLIN****Steering Committee Member, Quantitative Imaging Workshop**

Anita McGlothlin joined the GO₂ Foundation for Lung Cancer in 2018 as the director of Economics and Health Policy. Founded by patients and survivors, it is their mission to save, extend and improve the lives of those vulnerable, at-risk and diagnosed with lung cancer. Within this role, Ms. McGlothlin advances lung cancer screening and care through health policy, regulatory and coverage and reimbursement efforts.

Ms. McGlothlin works closely with Patient and Outreach Services and Science and Research programs to advance the Foundation's mission through the development and implementation of health policies. With over twenty years of experience in economics and health policy and having led low dose CT lung cancer screening national coverage efforts with radiology in her prior role, Ms. McGlothlin has a unique interest in reducing patient access barriers and increasing the lung cancer screening and survival rates.

With a focus in public policy, Ms. McGlothlin continues her work in lung cancer patient advocacy by serving on the National Lung Cancer Roundtable (NLCRT) Policy Action Task Group, and formerly served as their vice-chair.

amcglathlin@go2foundation.org

Twitter: [@GO2Foundation](https://twitter.com/GO2Foundation)

**ANDREA B. MCKEE, MD****James L. Mulshine, MD, National Leadership Award Recipient**

Dr. Andrea McKee is currently a radiation oncologist for Radiation Oncology Associates, PA practicing fulltime at Wentworth-Douglass Hospital's Seacoast Cancer Center in Dover and Portsmouth, New Hampshire where she is designated as successor for the position of medical director of Radiation Oncology; assistant professor at Tufts University School of Medicine; and former chair of the Department of Radiation Oncology at the Lahey Hospital & Medical Center (LHMC). In early 2012, Dr. McKee and a team of allied health professionals at LHMC initiated the Rescue Lung, Rescue Life community benefit CT lung screening program (CTLS) to save lives and open screening access to those at high-risk for lung cancer regardless of financial means. Dr. McKee assisted centers of excellence around the country to establish similar community benefit programs. At a critical time during the Centers for Medicare and Medicaid (CMS) CTLS National Coverage Determination process, Dr. McKee co-authored numerous seminal peer-reviewed publications on the design, implementation and management of high-quality clinical CT lung screening. Currently serving as president of the Rescue Lung Society, she continues to advance screening objectives alongside other physicians, researchers and patient advocates.

andrea.b.mckee@lahey.org

Twitter: [@arbmckee](https://twitter.com/arbmckee)

**BRADY J. MCKEE, MD****James L. Mulshine, MD, National Leadership Award Recipient (Posthumously Awarded)**

Dr. Brady McKee was section head of Thoracic Imaging and Cardiac CT in the Division of Radiology at Lahey Hospital & Medical Center (LHMC), an assistant professor at Tufts University School of Medicine, and co-founder of the CT lung screening program (CTLS) at LHMC. He led various initiatives to advance and improve clinical CTLS including originating the Lung-RADS® CTLS reporting system in 2011, now in use worldwide for standardized reporting of CTLS exams. Dr. McKee led the design and development of the Lung Academy, an online virtual CTLS learning and radiologist training environment. Dr. McKee also co-developed the model for the first dedicated commercially available clinical CTLS program management system in the US. He had lectured internationally on CTLS over the past seven years.

**PROVIDENCIA MORALES, MSN, RN, RT, CCRC**

Providencia Morales joined the Department of Veterans Affairs in 1985 as a registered respiratory therapist at the VA Medical Center (VAMC) in Phoenix, AZ. In her time with the Phoenix VAMC, she has held progressively responsible clinical and administrative roles such as staff nurse, quality specialist, and research nurse leader. Ms. Morales' nursing experience includes Intensive Care Unit, Ambulatory Care, Quality Management, Accreditation/Survey Readiness, Performance Measures, Lung Cancer Screening and Research Nurse Leader. Throughout her career, Ms. Morales has focused her experience on process improvement and guidance/interpretation. As a result, she provides specialized consultation as a subject-matter expert in project management and process improvement initiatives. In addition to her nursing and administrative roles, Ms. Morales functions as part of the Research administrative team advising Principal Investigators and study teams. Ms. Morales is recognized as analytical, results-oriented and innovative in contributing to organizational success and bridging the gap between clinical and administrative requirements.

providencia.morales@va.gov



JAMES L. MULSHINE, MD

Founder and Steering Committee Chair, Quantitative Imaging Workshop

Dr. James Mulshine is a professor at Rush University where he has served as associate provost and vice president for research as well as acting dean of the Graduate College. Prior to joining Rush University in 2005, Dr. Mulshine was at the National Cancer Institute (NCI) for 25 years, where he was on the research faculty. Internationally recognized as an expert on lung cancer, Dr. Mulshine's research concentrates on application of quantitative CT to enable robust, efficient early lung cancer detection. Beginning in 2003, Dr. Mulshine—in cooperation with the Prevent Cancer Foundation®—established the Quantitative Imaging Workshop. He has been awarded 12 patents and has more than 350 scientific and medical publications. Dr. Mulshine is on numerous editorial boards, as well as national and international scientific and foundation advisory boards, including serving as vice chairman and scientific director and vice chairman of the Prevent Cancer Foundation®. He has received numerous national and international recognition awards related to the impact of his research efforts on early cancer management most recently including the Aeschylus Award from the Bonnie J. Addario Foundation.

james.l.mulshine@rush.edu



JAMES O'DOHERTY, PhD, CSci, MIPEM, MPE

Dr. Jim O'Doherty is currently working as a research & development collaborations manager for Siemens Healthineers, where they develop new imaging techniques and software solutions in collaboration with clinical collaborators. Dr. O'Doherty has an academic post at the Medical University of South Carolina where he is based.

james.odoherty@siemens-healthineers.com

LinkedIn: www.linkedin.com/in/jimodoherty/



PAUL F. PINSKY, PhD, MPH

Dr. Paul Pinsky is the chief of the Early Detection Research Group, Division of Cancer Prevention, National Cancer Institute at the National Institutes of Health. He has a background in statistics, epidemiology and mathematical modeling. He has worked extensively with data from the Branch's two large screening trials, the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and the National Lung Screening Trial (NLST). His research pertaining to the trials has dealt with evaluating the direct and indirect effects of screening, examining factors that affect screening efficacy, and evaluating the burdens of screening.

Dr. Pinsky has also worked in the fields of mathematical modeling, especially of the natural history of cancer, epidemiology and statistical methods. He received an MPH in epidemiology from Columbia University and a PhD in applied mathematics from the University of Maryland, College Park. He has previously worked at the Centers for Disease Control and the Food and Drug Administration. Dr. Pinsky has published over 30 first-authored papers in cancer prevention and related fields.

pinskyp@mail.nih.gov



GINNIE PRATER, MD, CCD, CMD

Dr. Ginnie Prater is a medical director at Blue Cross and Blue Shield of Alabama. Her primary area of responsibility is utilization management. She also works with the Health Equity and Medicare Advantage teams.

Dr. Prater graduated from Indiana State University with a BS in Chemistry in 1999. She completed medical training at the University of Alabama School of Medicine. She maintains board certifications in Internal Medicine and Geriatric Medicine. Dr. Prater is a certified clinical densitometrist and a certified medical director.

Prior to her work at Blue Cross and Blue Shield of Alabama, Dr. Prater was a full-time academic geriatrician and clinician-educator. She continues to practice part-time at University of Alabama at Birmingham in the Osteoporosis Prevention and Treatment clinic. She continues to work with the International Society of Clinical Densitometry (ISCD) on the education committee, with a goal of enhancing the quality of musculoskeletal health assessments and treatments.

ginnie.prater@bcbsal.org

LinkedIn: linkedin.com/in/ginnie-prater-md-4694139



BRUCE S. PYENSON, FSA, MAAA

Steering Committee Member, Quantitative Imaging Workshop

Bruce Pyenson is principal and consulting actuary at Milliman, Inc., in New York. In his more than 35 years at Milliman, he has consulted to almost every sector of healthcare, including accountable care organizations (ACOs), employers, advocacy groups, insurers, and the biotechnology industry. Many of his projects involve integrating analytics from financial, clinical, and operational models.

In recent years, client projects have included the cost-benefit of lung cancer screening, the cost advantage of CT colonography, the impact of proposed changes to Medicare Part D, foundational work on healthcare value, marginal cost analyses using risk adjustment methodologies, feasibility analyses for ACOs, restructuring of disease management processes, and actuarial cost/benefit evaluations for pharmaceutical manufacturers.

Mr. Pyenson is a Fellow of the Society of Actuaries and a member of the American Academy of Actuaries. From 2016-2022 he was a commissioner on MedPAC, the Medicare Payment Advisory Commission, which advises Congress. He has served as an adjunct clinical associate professor of New York University's College of Global Public Health and is a member of the Institute for Healthcare Delivery Science at the Mount Sinai Health System. He serves on the Board of the International Early Lung Cancer Action Program. He was on the board of the Health Project (Koop Awards) from 2010-2016.

bruce.pyenson@milliman.com

Twitter: [@bruce-pyenson](https://twitter.com/bruce-pyenson)

LinkedIn: www.linkedin.com/in/brucepyenson



ALBERT A. RIZZO, MD, FACP

Steering Committee Member, Quantitative Imaging Workshop

James L. Mulshine, MD, National Leadership Award Presenter

Dr. Albert Rizzo, as chief medical officer for the American Lung Association, is the organization's senior medical authority. Dr. Rizzo has long been a key medical advisor to the Lung Association, a member of the Lung Cancer Expert Medical Advisory Panel and a leading media spokesperson. In his role as chief medical officer, Dr. Rizzo plays a key role in multiple areas of our mission, including the Lung Association's Lung HelpLine, research, and the Awards and Grants program as well as advocacy, communications, development and health promotions. Dr. Rizzo is responsible for ensuring that the Lung Association is always using the best science and medicine to formulate and deliver on our mission.

Dr. Rizzo is a member of Christiana Care Pulmonary Associates at the Christiana Care Health System in Newark, DE. He is board certified in internal medicine, pulmonary, critical care and sleep medicine and is a clinical assistant professor of medicine at Thomas Jefferson University Medical School in Philadelphia where he obtained his medical degree and completed his residency in internal medicine.

albert.rizzo@lung.org

Twitter: [@arizzomd](https://twitter.com/arizzomd)

LinkedIn: www.linkedin.com/in/albert-rizzo-bb15068/



RAJ SAREEN, MS

Raj Sareen is an entrepreneur, scientist and inventor who serves as the chief executive officer and co-founder of the fast-growing start-up [Styku](http://Styku.com), a 3D body scanning and body shape analysis system for health, fitness and wellness professionals. Mr. Sareen has a bachelor of science degree in Space Sciences, and a master of science degree in Physics. His journey has included stints at NASA, The Astrobiology Institute of Biomarkers, California and Carnegie Planet Search lab, and other notable research institutes. Having come from a family of entrepreneurs, Mr. Sareen fosters a deep desire to build innovative technology that can help further understanding of the world. In 2010, he pioneered a new class of 3D imaging systems using depth cameras for lifestyle businesses. Today, he finds himself fortunate in building markets for body scanning systems for lifestyle purposes, such as fitness, wellness, and health assessment. Mr. Sareen has been a guest lecturer on several occasions for a technology course at Harvard Business School and is a graduate of the prestigious Techstars Accelerator.

raj.sareen@styku.com

Twitter: [@Styku3D](https://twitter.com/Styku3D)

LinkedIn: www.linkedin.com/in/rajsareen/



EZEQUIEL “ZEKE” SILVA III, MD, FACR, FSIR, FRBMA, RCC

Dr. Ezequiel Silva is chair of the American Medical Association’s (AMA) Specialty Society RVS Update Committee (RUC) and serves as chair of the RUC Research Subcommittee. He is also immediate past co-chair of the AMA Digital Medicine Payment Advisory Group (DMPAG). He serves on the Texas Medical Association (TMA) Delegation to the American Medical Association and on the TMA Council on Legislation.

A graduate of the University of Texas at Austin, Dr. Silva completed medical school and residency at Baylor College of Medicine before pursuing a fellowship in vascular and interventional radiology at Massachusetts General Hospital. His clinical interests include digital applications in health care, particularly oncology imaging and interventions.

In San Antonio, Dr. Silva is a member of the board of directors for the South Texas Radiology Group and Diagnostic Imaging Management. He is the medical director of Radiology at the Methodist Texan Hospital. He is an adjunct professor at the UT Health-San Antonio. Locally, Dr. Silva was recently recognized as a “Health Care Hero” by the *San Antonio Business Journal* for his efforts around digital health during the COVID-19 public health emergency.

zekesilva3@gmail.com

Twitter: [@zekesilva3](https://twitter.com/zekesilva3)

LinkedIn: [linkedin.com/in/ezequiel-silva-990b3b184](https://www.linkedin.com/in/ezequiel-silva-990b3b184)



MARIO SILVA, MD, PhD

Dr. Mario Silva graduated in radiology at the University of Parma (Italy) and completed a research fellowship in Cardio-Pulmonary Imaging at the Beth Israel Deaconess Medical Center, Harvard Medical School in Boston, MA.

Dr. Silva is an active researcher in the field of thoracic imaging, including thoracic oncology. His main scientific interests are early diagnosis of lung cancer by screening with low-dose CT and the evolving scenario of medical treatment of pulmonary malignancies. He has authored or co-authored over 100 peer-reviewed articles published in international scientific journals, numerous abstracts at international congresses, and published book chapters on thoracic imaging. He was awarded the “Premio Pigorini” by the Italian College of Thoracic Radiologists (Società Italiana di Radiologie Medica, SIRM). He is member of the Institute for Diagnostic Accuracy within the European Union-funded H2020 project called 4-in-the-lung-run.

He is editor of the book *Tumor Dissemination Pathways – The Thorax* by Springer and also authored several book chapters on thoracic imaging including interstitial lung disease (Grainger and Allison’s 7th Edition - Elsevier) and artificial intelligence (De Cecco et al – Springer). He is reviewer for various international scientific journals. Dr. Silva is also the “Chest” Lead Section Editor of the *European Journal of Radiology*, moreover he serves as “Chest” associate editor of *the British Journal of Radiology*, and “Diagnostic Imaging” Section Editor of the *Tumori Journal*.

He is assistant professor in Radiology at the University of Parma (Italy) and adjunct assistant professor at the Department of Radiology, UMass Chan Medical School, University of Massachusetts.

During the 2020 pandemic of SARS-CoV-2 he served on the task force for the development of integrated clinic-radiological management of respiratory triage, at the University Hospital of Parma (doi: 10.1097/RTI.0000000000000516). In 2021-2022, he coordinated and wrote the position paper “Low-dose CT for Lung Cancer Screening: Position Paper from the Italian College of Thoracic Radiology” (doi: 10.1007/s11547-022-01471-y).

In private life, he enjoys his three-kid family and spending his free time motorcycling and windsurfing.

mario.silva@unipr.it



TIMOTHY P. SZCZYKUTOWICZ “STICK,” PhD

Dr. Timothy Szczykutowicz “Stick” is an associate professor of Radiology at the University of Wisconsin. He specializes in all things CT from reconstruction algorithms to technologist workflow. Protocols developed by his team have been shipped to 3,500 sites around the globe. His intellectual property (IP) is being licensed by two companies. He is currently on editorial boards at the *Journal of Computer Assisted Tomography*, *Journal of Thoracic Imaging*, and *Radiographics*. Dr. Szczykutowicz is the author of over 45 papers, two book chapters, the book *The CT Handbook: Optimizing Protocols for Today’s Feature-rich Scanners*, four patents, and is a consultant to five companies.

tszczykutowicz@uwhealth.org

Twitter: [@Prof_TimStick](https://twitter.com/Prof_TimStick)

LinkedIn: www.linkedin.com/in/timothy-szczykutowicz-190174144



DANIEL TSE, MD

Keynote Speaker – AI and Medical Imaging: Early Progress and Promise

Dr. Daniel Tse leads Google's Health AI efforts across research & development, productization, and go-to-market in a number of clinical domains. Before coming to Google, he was an early member of Watsi.org (Y-Combinator's first non-profit) building their medical program and health finance infrastructure in over 20 countries as well as at Palantir Technologies where he helped scale their commercial health care team and establish their Philanthropy team. Dr. Tse received his medical degree from Dartmouth Medical School and studied molecular genetics and bioinformatics at The Ohio State University.

tsetd@google.com

Twitter: [@GoogleHealth](https://twitter.com/GoogleHealth)

LinkedIn: www.linkedin.com/in/tsetsefly



ANIL VACHANI, MD, MS

Dr. Anil Vachani is a pulmonologist and physician-scientist at Penn Medicine and the Philadelphia VA Medical Center. He co-directs the Lung Cancer Screening (LCS) programs at both institutions and leads efforts to implement lung cancer screening. His research interests broadly focus on the studies that address important process and outcome questions relevant to the study of quality and comparative effectiveness of current approaches for prevention, screening, diagnosis and management of lung cancer and other thoracic malignancies. His current work, funded by the National Cancer Institute and Patient-Centered Outcomes Research Institute (PCORI), uses multicenter observational approaches and interventional studies to assess key outcomes relevant to LCS implementation. Dr. Vachani received his medical degree from the University of California, San Francisco, and completed a master's degree in clinical epidemiology from the University of Pennsylvania's Perelman School of Medicine.

avachani@pennmedicine.upenn.edu



GEORGE R. WASHKO, MMSc, MD

Dr. George Washko is a physician at Brigham and Women's Hospital (BWH). He is also an associate professor of medicine at Harvard Medical School.

He received his medical degree from Georgetown University School of Medicine. Dr. Washko then completed a residency in internal medicine at Beth Israel Deaconess Medical Center, followed by a fellowship in pulmonary and critical care medicine disease in the Harvard Combined Fellowship for Pulmonary and Critical Care Medicine. He is board certified in critical care medicine and pulmonary disease.

Dr. Washko is a National Institutes of Health-funded investigator in chronic obstructive pulmonary disease (COPD), specifically focusing his work in imaging and quantitative image analysis. He is also one of the co-primary investigators for the National Heart, Lung and Blood Institute-funded American Lung Association Lung Health Cohort (ALA-LHC). This study will enroll 4,000 millennials and ask them to undergo detailed characterization to understand the earliest manifestations of loss of lung health. Dr. Washko's lab leads multiple investigator-initiated studies and serves as an analytics core for federal and industry sponsored national and international clinical investigations. The breadth of these collaborations has provided investigators in Dr. Washko's lab the opportunity to identify and develop areas of interest that enable their transition to independence.

gwashko@bwh.harvard.edu



DAVID YANKELEVITZ, MD
Steering Committee Member, Quantitative Imaging Workshop

Dr. David Yankelevitz is a world-recognized expert on Fine Needle Aspirations (FNAs) of lung nodules; and he has developed one of the largest FNA practices in the United States, performing over 10,000 FNA procedures, to date.

He is the co-Principal Investigator (PI) of the International **Early Lung Cancer Action Program (I-ELCAP)** – a lung cancer screening study, which to date, has enrolled over 85,000 people around the world. He is also the co-Principal Investigator of the Initiative for **Early Lung Cancer Research on Treatment (IELCART)**, which started in 2016.

As a researcher, Dr. Yankelevitz's main clinical and academic interest is in the evaluation of treatments for early-diagnosed lung cancer and he has numerous collaborations with thoracic surgeons, pulmonologists, pathologists and molecular biologists on related projects. He led the development of software for volumetric analysis of pulmonary nodules – now a widely accepted tool supporting early diagnosis. In addition, he has been PI on three National Cancer Institute (NCI) grants related to this work and has performed the functions of a core lab for several clinical trials in early lung cancer, including development of protocols for saving small amounts of tissue from lung biopsies used for molecular testing, integrating tumor volume assessments, and correlating with molecular markers. Dr. Yankelevitz is working with industry on assessing liquid biopsies to be integrated into diagnostic and treatment approaches. He is a member of the American College of Radiology Committee on screening recommendations (Lung-RADS®).

In addition to his medical and research work, Dr. Yankelevitz has co-authored over 400 articles, abstracts and book chapters; and he has trained 80 research fellows in thoracic imaging. He has obtained 14 patents. Dr. Yankelevitz joined the faculty of the Icahn School of Medicine at Mount Sinai in 2010 as a radiologist and professor of Radiology. Prior to joining Mount Sinai, Dr. Yankelevitz was professor of Radiology at Weill Cornell Medical College.

david.yankelevitz@mountsinai.org



ROWENA YIP, MPH

Rowena Yip is a senior biostatistician in the Department of Diagnostic, Molecular and Interventional Radiology at the Icahn School of Medicine at Mount Sinai. She is also an affiliated member of the Biostatistics Shared Resource Facility at the Tisch Cancer Institute at Mount Sinai. Ms. Yip's research focuses on the application of statistical and epidemiological methods to critical diagnostic and therapeutic topics involved in lung cancer screening and treatment. Her recent work involves assessing the determinants of aggressive lung cancers, optimization of nodule management in CT lung cancer screening, and development of lung cancer risk prediction models. Ms. Yip is currently a PhD candidate, and she holds an MPH in biostatistics.

rowena.yip@mountsinai.org

LinkedIn: www.linkedin.com/in/rowena-yip-6b35495a



JAVIER J. ZULUETA, MD, FCCP

Dr. Javier Zulueta is professor of medicine at the Icahn School of Medicine and chief of the Pulmonary, Critical Care and Sleep Medicine Division at Mount Sinai Morningside Hospital in New York, NY. Previously, he served as associate professor and 20-year director of Pulmonary Medicine at the Clinica Universidad de Navarra, the teaching hospital of Spain's University of Navarra School of Medicine. He started in 2000 and led until 2020 the longest ongoing lung cancer screening trial in Europe as part of the I-ELCAP consortium. Dr. Zulueta's research interests include lung cancer screening, diagnosis of lung nodules, and the relationship between lung cancer, COPD and emphysema.

Dr. Zulueta also recently served as chief medical officer of VisionGate, Inc. He is a member of the Committee on Prevention and Early Detection of Lung Cancer of the International Association for the study of Lung Cancer (IASLC), a Fellow of the American College of Chest Physicians, and member of the American Thoracic Society, American Respiratory Society, European Respiratory Society and Spanish Association of Pulmonary Medicine and Thoracic Surgery. He has authored more than 100 publications in peer-reviewed journals and has been an invited lecturer at more than 100 international conferences.

Dr. Zulueta received his medical doctorate from the Universidad Complutense in Madrid, Spain. His specialization in pulmonary and critical care medicine was earned at Tufts Medical Center, Tufts University School of Medicine in Boston, MA.

javier.zulueta@mountsinai.org

Twitter: [@DrZulueta](https://twitter.com/DrZulueta)

LinkedIn: www.linkedin.com/in/javier-zulueta